Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 116

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 8
Chunk 116
---
-efficiencies resulting from the ongoing application of the Danaher Business System.

29

Sales Growth and Core Sales Growth

% Change Three-Month Period Ended September 26, 2025 vs. Comparable 2024 Period% Change Nine-Month Period Ended September 26, 2025 vs. Comparable 2024 PeriodTotal sales growth (GAAP)4.5 %2.5 %Impact of:Currency exchange rates (1.5)%(1.0)%Core sales growth (non-GAAP)3.0 %1.5 %

Operating Profit Performance 

Operating profit margins increased 260 basis points from 16.5% during the three-month period ended September 27, 2024 to 19.1% for the three-month period ended September 26, 2025.  

Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were favorably impacted by:

•Third quarter 2024 impairment charge related to a trade name in the Life Sciences segment, net of impairment charges related to technology and other assets in the Biotechnology segment and a trade name in the Diagnostics segment in the third quarter of 2025.  Refer to Note 8 to the accompanying Consolidated Condensed Financial Statements for additional information regarding the impairments - 220 basis points

•Higher 2025 core sales, net of the impact of changes in leverage from the Company’s operations and administrative cost structure and the impact of product mix - 45 basis points

Third quarter 2025 vs. third quarter 2024 operating profit margin comparisons were unfavorably impacted by:

•Incremental dilutive effect in 2025 of acquired businesses and the impact of a product line disposition which did not qualify as discontinued operations - 5 basis points

Operating profit margins decreased 180 basis points from 19.8% during the nine-month period ended September 27, 2024 to 18.0% for the nine-month period ended September 26, 2025.  

Year-to-date 2025 vs. year-to-date 2024 operating profit margin comparisons were unfavorably impacted by:

•First nine months of 2025 impairment charges related to trade names in the Life Sciences and Diagnostics segments, and impairment charges related to technology, other intangible assets and a facility in the Biotechnology segment, net of an impairment charge related to a trade name in the Life Sciences segment in the first nine months of 2024 - 180 basis points

•Incremental